Oscar Health (OSCR) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Oscar Health (NYSE: OSCR):

• 6/24/2026 – Oscar Health was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 6/14/2026 – Oscar Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/10/2026 – Oscar Health was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $35.00 price target on the stock, up from $30.00.
• 6/9/2026 – Oscar Health was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 6/6/2026 – Oscar Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/5/2026 – Oscar Health was downgraded by Zacks Research from “strong-buy” to “hold”.
• 6/4/2026 – Oscar Health was given a new $20.00 price target by Wells Fargo & Company. They now have an “equal weight” rating on the stock.
• 6/4/2026 – Oscar Health was upgraded by Wells Fargo & Company from “strong sell” to “hold”. They now have a $20.00 price target on the stock.
• 5/26/2026 – Oscar Health had its price target raised by Barclays PLC from $21.00 to $30.00. They now have an “equal weight” rating on the stock.
• 5/9/2026 – Oscar Health was upgraded by Wall Street Zen from “hold” to “strong-buy”.
• 5/7/2026 – Oscar Health had its price target raised by UBS Group AG from $15.00 to $20.00. They now have a “neutral” rating on the stock.
• 5/7/2026 – Oscar Health had its price target raised by Barclays PLC from $18.00 to $21.00. They now have an “equal weight” rating on the stock.
• 5/7/2026 – Oscar Health was upgraded by Zacks Research from “hold” to “strong-buy”.
• 5/7/2026 – Oscar Health had its price target raised by Robert W. Baird from $15.00 to $19.00. They now have a “neutral” rating on the stock.
• 5/5/2026 – Oscar Health is now covered by Wolfe Research. They set a “peer perform” rating on the stock.

Insider Activity at Oscar Health

In other Oscar Health news, CFO Richard Scott Blackley sold 100,000 shares of the stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $23.16, for a total transaction of $2,316,000.00. Following the completion of the transaction, the chief financial officer owned 1,216,660 shares of the company’s stock, valued at $28,177,845.60. This represents a 7.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Adam Mcananey sold 9,859 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $21.94, for a total value of $216,306.46. Following the transaction, the insider owned 218,096 shares of the company’s stock, valued at approximately $4,785,026.24. The trade was a 4.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 1,217,160 shares of company stock valued at $34,471,090 in the last ninety days. Corporate insiders own 25.11% of the company’s stock.

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.